Daniel Ching

28 papers receiving 416 citations

Peers

Daniel Ching
Comparison fields: 5 of 75
  • Cancer Research 103
  • Dermatology 48
  • Rheumatology 74
  • Immunology 91
  • Hematology 39
Replace Roger Llatjós with:
Roger Llatjós Spain
Nóra Béres Hungary
Ye Guo China
Andrea Ottria Netherlands
Eugénie Koumakis France
Lisa Kaly Israel
Mi Seon Kang South Korea
Maxine S. Emmett United Kingdom
Shelly Pathak United Kingdom
Tianbo Jin China
Daniel Ching relative to Roger Llatjós Spain Roger Llatjós's profile →
Citations per field
00.5×3.7×
Roger Llatjós · 1×
Citations per year

Countries citing papers authored by Daniel Ching

Since Specialization
Citations

This map shows the geographic impact of Daniel Ching's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Ching with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Ching more than expected).

Fields of papers citing papers by Daniel Ching

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel Ching. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Ching. The network helps show where Daniel Ching may publish in the future.

Co-authors

The 25 scholars most cited alongside Daniel Ching, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Daniel Ching Line = papers co-authored together Daniel Ching links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 28 papers — load more, or switch the sort, to bring in the rest.

#Work
1 2015166
2 201341
3 199031
4 200725
5 201324
6 201717
7 201414
8 201514
9 201914
10 201013
11 201910
12 201910
13 20207
14 20156
15 20155
16 20165
17 20195
18 20144
19 20174
20 20193

About Daniel Ching

Daniel Ching is a scholar working on Dermatology, Hematology, Rheumatology, Genetics and Neurology, having authored 28 papers that have together received 429 indexed citations. Recurring topics across this work include Chemotherapy-related skin toxicity (4 papers), Chronic Lymphocytic Leukemia Research (3 papers), Autoimmune and Inflammatory Disorders Research (3 papers), Cancer Treatment and Pharmacology (2 papers), Sphingolipid Metabolism and Signaling (2 papers), Neuroinflammation and Neurodegeneration Mechanisms (2 papers), Rheumatoid Arthritis Research and Therapies (2 papers) and Spondyloarthritis Studies and Treatments (2 papers). The work is most often cited by research in Cancer Research (103 citations), Dermatology (48 citations), Rheumatology (74 citations), Immunology (91 citations) and Hematology (39 citations). Daniel Ching has collaborated with scholars based in Australia, United Kingdom and United States. Frequent co-authors include Robert L. Raffaı̈, Kang Li, Kai Yuen Wong, Lisa K. Stamp, Marian E. Melish, N. J. Marchette, Andrew Harrison, Mark Soldin, Joel S. Karliner and Roy Kim. Their work appears in journals such as Annals of the Rheumatic Diseases, Lara D. Veeken, Journal of Cardiovascular Pharmacology, Pathology and International Journal of Surgery.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026